Movement Alert｜INNOVENT BIO Falls 3.01% in Regular Trading, Biotech Sector Under Pressure Amid NRDL Negotiation Uncertainty

Market Focus09-08

On September 8, INNOVENT BIO fell 3.01% in regular trading, trading at HK$98.3/share, with turnover of HK$270 million. The broader biotechnology sector weakened in tandem, with BEONE MEDICINES down 2.97% and AKESO down 0.68%.

The decline comes as markets await results from the National Reimbursement Drug List (NRDL) negotiations held on September 5-6, where INNOVENT BIO participated with five products under review, including the closely watched GLP-1 receptor agonist mazdutide, PCSK9 antibody, the first domestic CTLA-4 monoclonal antibody, and FLT3 inhibitor quizartinib. Pricing outcomes for these key pipeline assets remain unclear, adding near-term uncertainty.

The stock had surged over 10% to a record high on August 26 after reporting H1 net profit of RMB 1.253 billion, up 50.2% year-over-year, with product revenue jumping 56.7% to RMB 8.2 billion. Multiple brokerages subsequently raised target prices, with BOCOM International setting a HK$129 target. The current pullback reflects profit-taking from those highs amid pending negotiation clarity.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1159618663?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-08 11:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1159618663","market":"hk","top_or_hot":-1,"title":"Movement Alert｜INNOVENT BIO Falls 3.01% in Regular Trading, Biotech Sector Under Pressure Amid NRDL Negotiation Uncertainty","media":"Market Focus","content":"<p><p>On September 8, INNOVENT BIO fell 3.01% in regular trading, trading at HK$98.3/share, with turnover of HK$270 million. The broader biotechnology sector weakened in tandem, with BEONE MEDICINES down 2.97% and AKESO down 0.68%.</p><p>The decline comes as markets await results from the National Reimbursement Drug List (NRDL) negotiations held on September 5-6, where INNOVENT BIO participated with five products under review, including the closely watched GLP-1 receptor agonist mazdutide, PCSK9 antibody, the first domestic CTLA-4 monoclonal antibody, and FLT3 inhibitor quizartinib. Pricing outcomes for these key pipeline assets remain unclear, adding near-term uncertainty.</p><p>The stock had surged over 10% to a record high on August 26 after reporting H1 net profit of RMB 1.253 billion, up 50.2% year-over-year, with product revenue jumping 56.7% to RMB 8.2 billion. Multiple brokerages subsequently raised target prices, with BOCOM International setting a HK$129 target. The current pullback reflects profit-taking from those highs amid pending negotiation clarity.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜INNOVENT BIO Falls 3.01% in Regular Trading, Biotech Sector Under Pressure Amid NRDL Negotiation Uncertainty</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜INNOVENT BIO Falls 3.01% in Regular Trading, Biotech Sector Under Pressure Amid NRDL Negotiation Uncertainty\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-09-08 11:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On September 8, INNOVENT BIO fell 3.01% in regular trading, trading at HK$98.3/share, with turnover of HK$270 million. The broader biotechnology sector weakened in tandem, with BEONE MEDICINES down 2.97% and AKESO down 0.68%.</p><p>The decline comes as markets await results from the National Reimbursement Drug List (NRDL) negotiations held on September 5-6, where INNOVENT BIO participated with five products under review, including the closely watched GLP-1 receptor agonist mazdutide, PCSK9 antibody, the first domestic CTLA-4 monoclonal antibody, and FLT3 inhibitor quizartinib. Pricing outcomes for these key pipeline assets remain unclear, adding near-term uncertainty.</p><p>The stock had surged over 10% to a record high on August 26 after reporting H1 net profit of RMB 1.253 billion, up 50.2% year-over-year, with product revenue jumping 56.7% to RMB 8.2 billion. Multiple brokerages subsequently raised target prices, with BOCOM International setting a HK$129 target. The current pullback reflects profit-taking from those highs amid pending negotiation clarity.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01801","symbol_name":"信达生物","start_time":0,"source_url":"","article_id":"1159618663","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1159618663","pubTimestamp":1788836713,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On September 8, INNOVENT BIO fell 3.01% in regular trading, trading at HK$98.3/share, with turnover of HK$270 million. The broader biotechnology sector weakened in tandem, with BEONE MEDICINES down...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01801":"信达生物"},"translate_title":"走势警报|信达生物常规交易下跌3.01%，生物技术板块因NRDL谈判不确定性承压","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01801":1},"content_text":"On September 8, INNOVENT BIO fell 3.01% in regular trading, trading at HK$98.3/share, with turnover of HK$270 million. The broader biotechnology sector weakened in tandem, with BEONE MEDICINES down 2.97% and AKESO down 0.68%.The decline comes as markets await results from the National Reimbursement Drug List (NRDL) negotiations held on September 5-6, where INNOVENT BIO participated with five products under review, including the closely watched GLP-1 receptor agonist mazdutide, PCSK9 antibody, the first domestic CTLA-4 monoclonal antibody, and FLT3 inhibitor quizartinib. Pricing outcomes for these key pipeline assets remain unclear, adding near-term uncertainty.The stock had surged over 10% to a record high on August 26 after reporting H1 net profit of RMB 1.253 billion, up 50.2% year-over-year, with product revenue jumping 56.7% to RMB 8.2 billion. Multiple brokerages subsequently raised target prices, with BOCOM International setting a HK$129 target. The current pullback reflects profit-taking from those highs amid pending negotiation clarity.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.0","shortVersion":"4.50.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1159618663","isCrawlerRequest":true}